US · Healthcare · Biotechnology
EPS came in at -0.34 against a street estimate of -0.31 — a miss of 9.7%.
Analysts rate Wave Life Sciences Ltd a strong buy (17 buy, 2 hold, 0 sell out of 19) with an average price target of $18.06.
| Fund | Stake |
|---|---|
| RA Capital Management, LLC | 13.69% |
| BlackRock Inc | 9.75% |
| GSK PLC | 9.26% |
| Maverick Capital Ltd | 5.22% |
| Driehaus Capital Management LLC | 2.76% |
| PRIMECAP Management Company | 2.72% |
| FMR Inc | 2.50% |
| 683 Capital Management LLC | 2.49% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 WAVE LIFE SCIENCES LTD. - 10-Q SUMMARY (Q2 2026) HEADLINE NUMBERS • Cash Position: $368.0 million cash + $122.6 million marketable securities = $490 | 2026-07-30 |
| Results announced · Q3 2026 WAVE LIFE SCIENCES LTD. - Q2 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Cash, cash equivalents, and marketable securities: $490.6 million as of June | 2026-07-30 |
| Shareholder vote results · Q2 2026 WAVE LIFE SCIENCES LTD. – 8-K SUMMARY HEADLINE NUMBERS • Shareholder Vote Result: 155,190,836 shares voted in favor of redomiciliation scheme vs. 78 | 2026-06-26 |
| Reg FD disclosure · Q2 2026 WAVE LIFE SCIENCES LTD. - 8-K SUMMARY HEADLINE NUMBERS • Company: Wave Life Sciences Ltd., Singapore-incorporated biotech company • Trading Symbol: | 2026-05-18 |
| Proxy statement · Q2 2026 WAVE LIFE SCIENCES LTD. PROXY STATEMENT SUMMARY --- WHAT SHAREHOLDERS ARE VOTING ON • Vote Item: Approval of the Scheme of Arrangement to redomicil | 2026-05-07 |
| Quarterly report · Q1 2026 WAVE LIFE SCIENCES LTD. – FORM 10-Q SUMMARY (Q1 2026) HEADLINE NUMBERS • Cash Position: $544.6 million in cash and cash equivalents as of March 31, | 2026-04-28 |
| Results announced · Q2 2026 WAVE LIFE SCIENCES LTD. – Q1 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Cash position: $544.6 million as of March 31, 2026 (down from $602.1 million | 2026-04-28 |
| Annual report FY2025 WAVE LIFE SCIENCES LTD. – 10-K SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Company: Wave Life Sciences Ltd., clinical-stage biotechnology compan | 2026-02-26 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Wave Life Sciences Ltd — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-18.